文献速递妇科肿瘤

比较新辅助化疗后手术与放化疗治疗IB2-IIB期宫颈癌的随机III期研究:EORTC-55994

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.
PubMed 文献 · J Clin Oncol · 2023-09-01

这项多中心随机III期试验纳入626例IB2-IIB期宫颈癌患者,随机分为新辅助化疗后手术组(NACT-S,n=314)和标准同步放化疗组(CCRT,n=312)。中位随访8.7年后,5年总生存率在NACT-S组为72%(95%CI 66-77),CCRT组为76%(95%CI 70-80),差异无统计学意义。试验未能证明NACT-S的优效性,但两组并发症发生率和健康相关生活质量均可接受。

要点

  • NACT-S组5年OS为72%(95%CI 66-77),CCRT组为76%(95%CI 70-80),差异无统计学意义。
  • NACT-S组短期≥3级不良事件发生率为41%,CCRT组为23%,NACT-S组更常见。
  • CCRT组长期≥3级不良事件发生率为21%,NACT-S组为15%,CCRT组更常见。

核心结论

  • 试验未能证明新辅助化疗后手术(NACT-S)相较于同步放化疗(CCRT)的优效性,但两组并发症发生率和健康相关生活质量均可接受。

研究设计与样本

  • 欧洲癌症研究与治疗组织妇科癌症组开展的多中心随机III期试验,2002年5月至2014年1月纳入626例国际妇产科联盟IB2-IIb期宫颈癌患者,随机分为NACT-S组(n=314)和标准CCRT组(n=312)。
  • 主要终点为5年总生存率,次要终点包括无进展生存、总生存、毒性和健康相关生活质量。

主要发现

  • 中位随访8.7年后,198例患者(31.6%)死亡。
  • NACT-S组完成方案治疗223/314例(71%),CCRT组完成方案治疗257/312例(82%)。
  • NACT-S组未完成方案治疗的主要原因包括毒性(30/314;9.6%)和疾病进展(21/314;6.7%);CCRT组为毒性(23/312;7.4%)和患者拒绝(13/312;4.2%)。
  • 完成NACT-S后接受额外放疗者107例(48%),完成CCRT后接受额外手术者20例(8%)。
  • 短期≥3级不良事件在NACT-S组更常见(41% vs 23%),长期≥3级不良事件在CCRT组更常见(21% vs 15%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This multicenter trial by the European Organisation for Research and Treatment of Cancer Gynecological Cancer Group was motivated by conflicting evidence on the value of neoadjuvant chemotherapy before surgery compared with concomitant chemoradiotherapy (CCRT) in stage IB2-IIB cervical carcinoma. METHODS: Between May 2002 and January 2014, 626 patients with International Federation of Gynecology and Obstetrics stage IB2-IIb were randomly assigned between neoadjuvant chemotherapy followed by surgery (NACT-S; n = 314) and standard CCRT (n = 312). The primary end point was 5-year overall survival (OS) rate. Secondary end points were progression-free survival, OS, toxicity, and health-related quality of life (HRQOL). RESULTS: After a median follow-up of 8.7 years, 198 patients (31.6%) died. Age, stage, and cell type were balanced in both arms. Protocol treatment was completed in 223 of 314 (71%) patients in NACT-S and 257 of 312(82%) in CCRT arms. Main reasons for incomplete protocol treatment were toxicity (30 of 314; 9.6%) and progressive disease (21 of 314; 6.7%) in the NACT-S arm and toxicity (23 of 312; 7.4%) and patient refusal (13 of 312; 4.2%) in the CCRT arm. Additional radiotherapy after completed NACT-S was given to 107 patients (48%), and additional surgery to 20 patients (8%) after completed CCRT. Short-term adverse events (AEs) ≥grade 3 occurred more frequently with NACT-S (41% v 23%), and long-term AEs ≥grade 3 more often with CCRT (21% v 15%). The 5-year OS was not significantly different between NACT-S (72%; 95% CI, 66 to 77) and CCRT (76%; 95% CI, 70 to 80). CONCLUSION: This trial failed to demonstrate superiority in favor of the NACT-S arm but resulted in acceptable morbidity and HRQOL in both arms.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kenter GG, Greggi S, Vergote I, et al. Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994. J Clin Oncol. 2023. PMID: 37656948. doi:10.1200/JCO.22.02852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。